

Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue

Jyoti Roy^{1,2}, Karson S. Putt¹, Domenico Coppola³, Marino E. Leon³, Farah K. Khalil³, Barbara A. Centeno³, Noel Clark⁴, Valerie E. Stark⁵, David L. Morse⁵ and Philip S. Low^{1,2}

¹Center for Drug Discovery, Purdue University, West Lafayette IN 47907 USA

²Department of Chemistry, Purdue University, West Lafayette IN 47907 USA

³Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa FL 33612 USA

⁴Tissue Core, H. Lee Moffitt Cancer Center, Tampa FL 33612 USA

⁵Department of Cancer Imaging and Metabolism, Imaging and Technology Center of Excellence, H. Lee Moffitt Cancer Center, Tampa FL 33612 USA

Published: March 05, 2025

Copyright: © 2025 Roy et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The Supplementary Material file has been added to this article.

Original article: Oncotarget. 2016; 7:14605–14615. <https://doi.org/10.18632/oncotarget.7522>